BMS-986242

Cat. No.:	HY-139204
CAS No.:	1923844-48-7
Molecular Formula:	$C_{24}H_{24}ClFN_2O$
Molecular Weight:	410.91
Target:	Indoleamine 2,3-Dioxygenase (IDO)
Pathway:	Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (608.41 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.4336 mL	12.1681 mL	24.3362 mL
5 mM	0.4867 mL	2.4336 mL	4.8672 mL
10 mM	0.2434 mL	1.2168 mL	2.4336 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (5.06 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (5.06 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

BMS-986242 is an orally active, potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor. BMS-986242 can be used for the research of cancer[1].

IC_{50} & Target

IDO1

In Vitro

BMS-986242 is more prone to oxidative metabolism and less susceptible to glucuronidation. BMS-986242 shows IC_{50}>25 μM for all targets except nAChR a1 (IC_{50}=12.3 μM) and nAChR a7 (IC_{50}>6 μM with -20 % max inhibition)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BMS-986242 (3~30 mg/kg; p.o.; 0~24 hours) exhibits dose-proportional exposure and a statistically significant reduction in

kynurenine concentration in the tumor at all three doses[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	nu/nu Mouse[1]
Dosage:	3~30 mg/kg
Administration:	P.o.
Result:	Exhibited dose-proportional exposure and a statistically significant reduction in kynurenine concentration in the tumor at all three doses.

CUSTOMER VALIDATION

- Toxicol Appl Pharmacol. 2022 Feb 11;115921.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Cherney EC, et al. Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1. ACS Med Chem Lett. 2021;12(2):288-294. Published 2021 Jan 28.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA